Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1636 1674
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19343405 | THERAPEUTIC CIRCULAR DNA FORMS | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 17443702 | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17622048 | NEURODEGENERATIVE DISEASE THERAPIES UTILIZING THE SKIN-BRAIN AXIS | Non-Final OA | Ohio State Innovation Foundation |
| 18171130 | USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 19085810 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | Final Rejection | E-Therapeutics PLC |
| 17906444 | HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 17602035 | Pharmaceutical Composition for Treating Muscle Disease | Final Rejection | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 18009069 | USE OF MICRO-RNA TO IMPROVE AND TREAT CHRONIC PHASE CARDIAC FUNCTION | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM |
| 18415999 | Increasing Specificity for RNA-Guided Genome Editing | Final Rejection | The General Hospital Corporation |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17945151 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17794637 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17792661 | INHIBITION OF TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS (TROLLS) IN THE TREATMENT OF CANCER | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17160050 | TARGETING GENE AMPLIFICATION IN CANCER USING TRIPLEX FORMATION AS A THERAPEUTIC STRATEGY | Final Rejection | Yale University |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | Final Rejection | University of Virginia Patent Foundation |
| 17625545 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE | Non-Final OA | The Governors of the University of Alberta |
| 18006820 | MIR-96-5P INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Final Rejection | TEIKYO UNIVERSITY |
| 18326912 | METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 17616599 | EPH2A APTAMER AND USES THEREOF | Non-Final OA | UNIVERSITY OF IOWA RESEARCH FOUNDATION |
| 18016109 | METHODS AND COMPOSITIONS FOR CRISPR/CAS9 GUIDE RNA EFFICIENCY AND SPECIFICITY AGAINST GENETICALLY DIVERSE HIV-1 ISOLATES | Final Rejection | Trustees Of Dartmouth College |
| 17798339 | RNAS FOR COMPLEMENT INHIBITION | Final Rejection | Apellis Pharmaceuticals, Inc. |
| 17772107 | TREATMENT OF RENAL CYSTIC DISEASE | Final Rejection | MONASH UNIVERSITY |
| 18282402 | TMEM173 saRNA Compositions and Methods of Use | Non-Final OA | MiNA Therapeutics Limited |
| 18277965 | FORMULATIONS FOR AEROSOL FORMATION AND AEROSOLS FOR THE DELIVERY OF NUCLEIC ACID | Non-Final OA | ethris GmbH |
| 18012031 | METHODS AND COMPOSITIONS FOR EDITING THE B2M LOCUS IN B CELLS | Final Rejection | SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) |
| 17869611 | METHODS FOR LABELING AND TARGETING CELLS | Non-Final OA | Whitehead Institute for Biomedical Research |
| 18331311 | MODULATION OF GYS1 EXPRESSION | Final Rejection | The Hospital for Sick Children |
| 18247961 | IMMUNOTHERAPY FOR THE TREATMENT OF CANCER | Non-Final OA | TARGIMMUNE THERAPEUTICS AG |
| 18252153 | GENE THERAPY BASED ADMINISTRATION OF LENTIVIRUS VECTOR FOR TREATING HEMOGLOBINOPATHIES | Non-Final OA | INTAS PHARMACEUTICALS LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy